117
Participants
Start Date
April 30, 2024
Primary Completion Date
April 30, 2026
Study Completion Date
April 30, 2027
JS001
240 mg by IV infusionevery 3 weeks (Q3W), given on cycle day 1.
JS004
200 mg by IV infusion Q3W, given on cycle day 1.
JS007
3mg/kg by IV infusion Q3W, given on cycle day 1.
JS015
600mg by IV infusion Q3W, given on cycle day 1.
Irinotecan Liposome Injection
60 or 70 mg/m\^2 by IV infusion every 2 weeks (Q2W), given on cycle day 1.
5-Fluorouracil (5-FU)
2400mg/m\^2, intravenously, over 46 h on day 1, Q2W.
Leucovorin (LV)
400mg/m\^2, intravenously, over 30 min on day 1, Q2W.
Nab paclitaxel
125 mg/m\^2 by IV infusion Q3W, given on cycle day 1 and 8.
Gemcitabine
1000 mg/m\^2 by IV infusion Q3W, given on cycle day 1 and 8.
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University, Shanghai
Fudan University
OTHER